Sponsor Overview
Explore verified public information about ORIC Pharmaceuticals's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“ORIC Pharmaceuticals, Inc. (ORIC) is committed to developing innovative therapies for cancer and is currently in the early stages of clinical development. However, in rare cases, where patients may not qualify for a particular clinical trial and have exhausted all available treatment options, ORIC may consider providing access to one of its investigational products outside of an ORIC-sponsored clinical trial to a limited number of doctors who are treating patients with an immediately life-threatening condition or serious disease or condition through a process called expanded access, also known as compassionate use.”
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.